RxDoctor Payments Data

Michael Rogers, MD

Family Medicine · West Deptford, NJNPI 1184684268

Payments from drug & device makers

$6,349in general payments, 2019–2025

Across 412 payments — averaging $15.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$810
  • Pfizer$631
  • GSK$523
  • Lilly USA, LLC$335
  • Globus Medical$326
  • plus $3K from 41 others

What the payments were for

  • Travel & lodging$3265%
  • Food & beverage$6,02395%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,349 in reported general payments places this provider in the 90th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$159,453
Medicare patients
448
Services billed
1,737

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban44$40,760
OzempicSemaglutide28$38,859
TrulicityDulaglutide27$26,030
MounjaroTirzepatide13$24,683
JardianceEmpagliflozin15$23,103
FarxigaDapagliflozin Propanediol19$21,912
JanuviaSitagliptin Phosphate11$14,270
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,210
EntrestoSacubitril/Valsartan11$7,448
Fluticasone-SalmeterolFluticasone Propion/Salmeterol27$5,741
Atorvastatin Calcium322$3,695
Pantoprazole Sodium90$1,915
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide173$1,675
Diltiazem 24hr Er (Cd)Diltiazem Hcl23$1,396
Lisinopril171$1,381

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$335$50,71440 claims
PfizerEliquis$631$40,76044 claims
Novo NordiskOzempic$810$38,85928 claims
Boehringer IngelheimJardiance$88$23,10315 claims
AstraZenecaFarxiga$253$21,91219 claims
MerckJanuvia$14$14,27011 claims
GSKTrelegy Ellipta$523$9,21013 claims
NovartisEntresto$46$7,44811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in West Deptford

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →